• Pubblicazione:
• Mayo Clinic Proceedings 90:6-756-764, 2015 - I.F. 7,61

107 – Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients

• AUTORI: Tadmor T., Bari A., Marcheselli L., Sacchi S., Aviv A., Baldini L. et al.

OBJECTIVE: To verify whether absolute monocyte count (AMC) and lymphocyte- monocyte ratio (LMR) at diagnosis are valid prognostic parameters in classical Hodgkin lymphoma (cHL).

• LEGGI

• Pubblicazione:
• British Journal of Haematololy 169:4-544:551, 2015 - I.F. 6,99

106 – Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi

• AUTORI: Marcheselli L., Bari A., Anastasia A., Botto B., Puccini B. et al.

Recently, in an attempt to improve the discrimination power of the international prognostic index (IPI), patients with diffuse large B-cell lymphoma were evaluated to

• LEGGI

• Pubblicazione:
• Annals of Epidemiology 25:8-564:568, 2015 - I.F. 3,79

105 – Cancer incidence, mortality, and survival in Eastern Libya: updated report from the Benghazi Cancer Registry

• AUTORI: El Mistiri M., Salati M., Marcheselli L., Attia A., Habil S. et al.

Purpose: Despite the increasing burden of cancer occurred over recent years in the African continent, epidemiologic data from Northern Africa area have been so

• LEGGI

• Pubblicazione:
• International Journal of Cancer 137:6-1417:1426, 2015 - I.F. 7,39

104 – Twenty-years experience with de novo metastatic breast cancer

• AUTORI: Cortesi L., Toss A., Cirilli C., Marcheselli L., Braghiroli B., Sebastiani F., Federico M.

Although new treatments have been widely studied to improve the survival of patients with metastatic breast cancer (BC), prognosis continues to be poor with

• LEGGI

• Pubblicazione:
• Hematological Oncology 33:4-166:175, 2015 - I.F. 5,27

103 – The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines

• AUTORI: Cosenza M., Civallero M., Pozzi S., Marcheselli L., Bari A., Sacchi S.

We analyzed the combination of a proteasome inhibitor (bortezomib) with enzastaurin (PKC/AKT-inhibitor) or lenalidomide (immunomodulatory agent) for the inhibition of proliferation and induction of

• LEGGI

• Pubblicazione:
• Britisch JOurnal of Haematology 165:6-892, 2014 - I.F. 6,99

102 – Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma-response to Murphy et al

• AUTORI: Pozzi S., Bari A., Sacchi S.

The study by Murphy et al supports the observation made by several groups regarding the benefit of the novel agents in both young and

• LEGGI

• Pubblicazione:
• Expert Opinion Investig Drugs 23:5-711:718, 2014 - I.F. 6,20

101 – The Potential Of Pralatrexate As A Treatment Of Peripheral T-Cell Lymphoma

• AUTORI: Dondi A., Bari A., Pozzi S., Ferri P., Sacchi S.

Introduction: Peripheral T-cell lymphomas (PTCLs) are a group of rare malignancies originating from clonal proliferation of mature, post-thymic T cells that represent 10 —

• LEGGI

• Pubblicazione:
• Journal Clinical of Oncology 32:12-1188:1194, 2014 - I.F. 44,54

100 – Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial

• AUTORI: Raemaekers JM., André MP., Federico M., Girinsky T., Oumedaly R., Brusamolino E., Brice P. et al.

Purpose Combined-modality treatment is standard treatment for patients with clinical stage I/II Hodgkin lymphoma (HL). We hypothesized that an early positron emission tomography (PET)

• LEGGI

• Pubblicazione:
• Hematological Oncology 33:3-147:151 2014 - I.F. 5,27

99 – Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry

• AUTORI: Biasoli I., Cesaretti M., Bellei M., Maiorana A., Bonacorsi G., Quaresima M. et al. et al.

We conducted a population-based study to establish the outcome of T-cell lymphoma (TCL) patients failing systemic first-line therapy. All TCL patients failing first-line systemic

• LEGGI

• Pubblicazione:
• Annals of Oncology 25-442:447, 2014 - I.F. 32,97

98 – The prognostic role of post-induction FDG-PET in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)

• AUTORI: Luminari S., Biasoli I., Versari A., Rattotti S., Bottelli C., Rusconi C., Merli F., Spina M., Ferreri A.J.M., Zinzani P.L. et al.

Background: [ 18F]fluorodeoxyglucose-positron emission tomography (PET) is emerging as a strong diagnostic and prognostic tool in follicular lymphoma (FL) patients. Patients and methods: In

• LEGGI

• Pubblicazione:
• Haematologica 99:1-125:130, 2014 - I.F. 9,54

97 – Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era

• AUTORI: Tadmor T., Bari A., Sacchi S., Marcheselli L., Liardo EV., Avivi I., Beniamini N. et al.

In this study we assessed the prognostic significance of absolute monocyte count and elected the best cut-off value at diagnosis, in a large cohort

• LEGGI

• Pubblicazione:
• Annals of Oncology 25-57:63, 2014 - I.F. 32,97

96 – A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women

• AUTORI: Cortesi L., Razzaboni E., Toss A., De Matteis E., Marchi I., Medici V., Tazzioli G., Andreotti A., De Santis G., Pignatti M., Federico M.

Background: Risk-reducing mastectomy (RRM) decreases breast cancer (BC) risk in BRCA1/2 mutation carriers by up to 95%, but the Italian attitude towards this procedure

• LEGGI

• Pubblicazione:
• Professioni Infermieristiche 67:1-55:56, 2014

95 – The undergraduate nursing student evaluation of clinical learning enviroment: an italian survey

• AUTORI: Magnani D., Di Lorenzo R., Bari A., Pozzi S., Del Giovane C., Ferri P.

Background: Nursing students have to deal with many different clinical and practical aspects of knowledge to become skilled professionals. Student perception may be considered

• LEGGI

• Pubblicazione:
• Blood 122:23-3759:3766, 2013 - I.F. 22,11

94 – Persistence Of Minimal Residual Disease In Bone Marrow Predicts Outcome In Follicular Lymphomas Treated With A Rituximab-Intensive Program

• AUTORI: Ladetto M , Lobetti-Bodoni C , Mantoan B , Ceccarelli M , Boccomini C , Bari A et al.

We assessed the prognostic value of minimal residual disease (MRD) within the ML17638 phase 3 trial from the Fondazione Italiana Linfomi, investigating the role

• LEGGI

• Pubblicazione:
• British Journal of Haematology 163:1-40:46, 2013 - I.F. 6,99

93 – Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis

• AUTORI: Pozzi S., Marcheselli L., Bari A., Liardo EV., Marcheselli R. et al.

Novel treatments for multiple myeloma (MM) have shown promising results in clinical trials, but the advantage in unselected patients is still unclear. In order

• LEGGI

• Pubblicazione:
• Journal Clinical of Oncology 31:27-3351:3359, 2013 - I.F. 44,54

92 – Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi

• AUTORI: Vitolo U., Ladetto M., Boccomini C., Baldini L., De Angelis F., Bari A. et al.

Purpose To evaluate the efficacy of rituximab maintenance in 60- to 75-year-old patients with advanced follicular lymphoma responding to brief first-line chemoimmunotherapy followed by

• LEGGI

• Pubblicazione:
• Leukemia Research 37:6-619:623, 2013 - I.F. 3,15

91 – Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas

• AUTORI: Bari A., Tadmor T., Sacchi S., Marcheselli L. et al.

In this retrospective study we evaluated the prognostic impact of peripheral blood monocytosis in patients with T-cell non Hodgkin lymphomas with “aggressive-typically nodal presentation”.

• LEGGI

• Pubblicazione:
• European Journal of Haematology 90:4-345:348 2013 - I.F. 2,99

90 – Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia

• AUTORI: Voso MT., Breccia M., Lunghi M., Poloni A., Niscola P., Bari A. et al.

In patients with myelodysplastic syndromes (MDS), the likelihood of having a sustained response to azacitidine is increased by maximizing treatment duration. This is important

• LEGGI

• Pubblicazione:
• International Journal of Molecolar Sciences 14:4-8271:8290, 2013 - I.F. 5,54

89 – Ovaria cancer: can proteomics give new insights for therapy and diagnosis?

• AUTORI: Toss A., De Matteis E., Rossi E., Della Casa L., Iannone A., Federico M., Cortesi L.,

The study of the ovarian proteomic profile represents a new frontier in ovarian cancer research, since this approach is able to enlighten the wide

• LEGGI

• Pubblicazione:
• Annals of Oncology 24:8-2108-2112, 2013 - I.F. 32,97

88 – The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from FOLL05 randomized trial of the Fondazione Italiana Linfomi

• AUTORI: Luminari S., Biasoli I., Arcaini L., Versari A., Rusconi C., Merli F., Spina M., Ferreri AJM., Zinzani PL., Gallamini A., Mastronardi S., Boccomini C., Gaidano G., D’Arco A.M., Di Raimondo F., Carella AM., Santoro A., Musto P., Federico M.

Background: The role of [¹⁸F] fluorodeoxyglucose (FDG)-positron emission tomography (PET) in follicular lymphoma (FL) staging is not yet determined. Patients and methods: The aim

• LEGGI

• Pubblicazione:
• Jornal of Clinical Oncology 31:2-:240:246, 2013 - I.F. 44,54

87 – Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project

• AUTORI: Federico M., Rudiger T., Bellei M., Nathwani BN., Luminari S., Coiffier B. et al.

Purpose The International Peripheral T-Cell Lymphoma Project was undertaken to better understand the subtypes of T-cell and natural killer (NK) – cell lymphomas. Patients

• LEGGI

• Pubblicazione:
• Leukemia & Lymphoma 54:1-53:57, 2013 - I.F. 3,28

86 – Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study

• AUTORI: Carella AM., de Souza CA., Luminari S., Marcheselli L., Chiappella A., Federico M. et al.

Male gender was recently reported as an adverse prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin,

• LEGGI

• Pubblicazione:
• International Journal of Cancer 132:2-ES8:65, 2013 - I.F. 7,39

85 – Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years

• AUTORI: Cortesi L., Marcheselli L., Guarneri V., Cirilli C., Braghiroli B., Federico M. et al.

Breast cancer prognosis has improved greatly in recent years. Consequently, a thorough search for sensitive prognostic factors, able to help clinicians offer appropriate therapy,

• LEGGI

• Pubblicazione:
• Hematological Oncology 31:2-72:78, 2012 - I.F. 5,27

84 – Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions

• AUTORI: Falorio S., Biasoli I., Luminari S., Quintana G., Musso M., Federico M. et al. -

Hodgkin lymphoma (HL) is one of the most common types of cancer in the young and one of the most curable forms of cancer.

• LEGGI

• Pubblicazione:
• Tumori 98:6-743:750, 2012 - I.F. 2,09

83 – Outcome evaluation in pre- trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women

• AUTORI: Cortesi L., De Matteis E., Cirilli C., Marcheselli L., Proietto M., Federico M.

Aims and background: Based on estrogen receptor (ER), progesterone receptor (PgR) and Her2/neu (HER2) expression, four breast cancer subtypes have been distinguished: luminal A

• LEGGI

• Pubblicazione:
• Expert Opinion Investigative Drugs 21:11-1597:1606, 2012 - I.F. 6,20

82 – NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy

• AUTORI: Civallero M., Cosenza M., Marcheselli L., Pozzi S., Sacchi S.

Objectives: Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma; the complete response rate for standard therapies in use today is 85

• LEGGI

• Pubblicazione:
• Annals of Hematology 91:10-1613:1622, 2012 - I.F. 3,67

81 – Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines

• AUTORI: Cosenza M., Civallero M., Grisendi G., Marcheselli L., Roat E., Sacchi S. et al.

Less toxic and more active treatments are needed for indolent lymphomas as there is no curative treatment, and patients eventually die due to complications

• LEGGI

• Pubblicazione:
• J Surg Oncol. 2012 Sep 15;106(4):399-405 - I.F. 3,45

80 – Prognosis and treatment of micrometastatic breast cancer sentinel lymph node: a population-based study

• AUTORI: Cortesi L , Proietto M , Cirilli C , Tazzioli G , Andreotti A , Federico M

Background and Objectives: Major concern of sentinel lymph node (SLN) biopsy (SLNB) regards the prognosis of micrometastasis (Nmic) in SLN. The purpose of this

• LEGGI

• Pubblicazione:
• Journal of Clinical Oncology 30:31-3848:3853, 2012 - I.F. 44,54

79 – Watchful Waiting in Low-Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database

• AUTORI: Solal-Céligny P., Bellei M., Marcheselli L., Pesce EA., Pileri S., Federico M. et al.

Purpose Patients with follicular lymphoma (FL) registered in the F2-study and initially managed without treatment were analyzed to describe the presentation and outcome of

• LEGGI

• Pubblicazione:
• Neoplasia 14:7-634:643, 2012 - I.F. 5,71

78- The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform

• AUTORI: Cattelani S., Ferrari-Amorotti G., Galavotti S., Defferrari R., Tanno B., Calabretta B. et al

The p53 gene is rarely mutated in neuroblastoma, but codon 72 polymorphism that modulates its proapoptotic activity might influence cancer risk and clinical outcome.

• LEGGI

• Pubblicazione:
• Current Women’s Health Reviews 8-72:85, 2012

77 – Radiological screening programs for women at high risk of developing breast cancer

• AUTORI: Cortesi L., De Matteis E., Sebastiani F., Toss A., Marchi I., Battista R., Canossi B., Pecchi A.R., Federico M.

The aim of this review is to identify the evidence for the surveillance of women at high risk of breast cancer with the different

• LEGGI

• Pubblicazione:
• Breast Cancer Res Treat 134:1-435:441, 2012 - I.F. 4,87

76 – Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat

• AUTORI: Cortesi L.., De Nicolo A., Medici V., Marino M., Turchetti D., Federico M. et al

Unambiguous classification of BRCA1 and BRCA2 variants of uncertain significance (VUS) is a challenging task that vexes health care providers and has profound implications

• LEGGI

• Pubblicazione:
• Leukemia & Lymphoma 53:4-581:588, 2012 - I.F. 3,28

75 – Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi

• AUTORI: Merli F., Luminari S., Rossi G . Mammi C., Marcheselli L., Federico M. et al

We conducted a prospective study to compare epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab (R-miniCEOP) with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOP) for the

• LEGGI

• Pubblicazione:
• Revista Brasileira de Hematologia e Hemoterapia 34:1-42:47, 2012 - I.F. 0,99

74 – T-cell lymphomas in South America and Europe

• AUTORI: Bellei M., Chiattone CS., Luminari S., Pesce EA. et al.

Peripheral T-cell lymphomas are a group of rare neoplasms originating from clonal proliferation of mature post-thymic lymphocytes with different entities having specific biological characteristics

• LEGGI

• Pubblicazione:
• Revista Brasileira de Hematologia e Hematerapia 34:1-48:53, 2012 - I.F. 0,99

73 – Fertility in female survivors of Hodgkin’s lymphoma

• AUTORI: Biasoli I., Falorio S., Luminari S., Spector N., Federico M.

Currently, Hodgkin’s lymphoma is one of the most curable types of cancer. Patients are often young and so the long-term morbidities of treatment have

• LEGGI

• Pubblicazione:
• Hematology Oncology 29:3-154:156, 2011 - I.F. 5,27

72 – Genomic profiling of enzastaurin-treated B cell lymphoma RL cells

• AUTORI: Civallero M., Cosenza M., Neri A., Bari A.

Follicular lymphoma (FL) is an indolent lymphoma associated with follicular centre B cells and typically contains the Bcl-2 chromosomal translocation t(14;18). FLs are sensitive

• LEGGI

• Pubblicazione:
• British Journal of Hematology 156:3-346:353, 2012 - I.F. 6,99

71 – Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial tretment of patients with mantle cell lymphoma: a multicentre trial from Gruppo Italiano Studio Linfomi.

• AUTORI: Merli F., Luminari S., Ilariucci F., Petrini M., Visco C., Ambrosetti A., Stelitano C., Caracciolo F., Di Renzo N., Angrilli F., Carella A.M., Capodanno I., Barbolini E., Galimberti S., Federico M.

This study investigated the clinical activity and toxicity of R-HCVAD-AM [rituximab plus HyperCVAD (R-HCVAD) alternating with high-dose cytarabine and methotrexate (AM)] in patients with

• LEGGI

• Pubblicazione:
• Leukemia & Lymphoma 52:9-1689:1696, 2011 - I.F. 3,28

70 – Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a populationbased study from Northern Italy

• AUTORI: Stefano Luminari, Marina Cesaretti, Chiara Tomasello, Annalisa Guida, Bruno Bagni, Massimo Federico et al.

We conducted a population-based study to assess how positron emission tomography (PET) is currently used in patients with Hodgkin lymphoma (HL). Four cancer registries

• LEGGI

• Pubblicazione:
• Leukemia & Lymphoma 52:10-1942:194-8, 2011 - I.F. 3,28

69 – A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant

• AUTORI: Stefano Sacchi, Raffaella Marcheselli, Antonio Lazzaro, Fortunato Morabito, Alberto Fragasso, Luciano Masini

Several trials comparing the efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in elderly patients with multiple myeloma (MM)

• LEGGI

• Pubblicazione:
• Annals of Oncology 22:8-1845:1858, 2011 - I.F. 32,97

68 – Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis

• AUTORI: Pirani M., Marcheselli R., Marcheselli L., Bari A., Federico M., Sacchi S.

Background: Late side-effects are becoming an important issue in non-Hodgkin’s lymphoma (NHL) survivors. We intended to estimate pooled relative risk (RR) of secondary malignant

• LEGGI

• Pubblicazione:
• Expert Opinion on Investigational Drugs 20:8-1029:1031, 2011 - I.F. 6,20

67 – Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin’s lymphoma

• AUTORI: Civallero M., Cosenza M., Bari A., Sacchi S.

Non-Hodgkin’s lymphoma (NHL) is the most common hematologic malignant neoplasm in adults [1]. Combination chemotherapy regimens have been the mainstay of treatment for NHL

• LEGGI

• Pubblicazione:
• Leukemia & Lymphoma 52:10-1867:1872, 2011 - I.F. 3,28

66 – Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma

• AUTORI: Marcheselli L., Marcheselli R., Bari A., Liardo E., Morabito F., Sacchi S. et al.

The effects of radiotherapy (RT) after chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL) remain unclear; several trials have yielded conflicting results. This

• LEGGI

• Pubblicazione:
• Electrophoresis 32:15-1992:2003, 2011 - I.F. 3,53

65 – Protein expression patterns associated with advanced stage ovarian cancer

• AUTORI: Laura Cortesi, Elena Rossi, Lara Della Casa, Andrea Barchett , Alessia Nicoli, Anna Iannone et al.

This is a comparative proteomic study on biopsies from patients with ovarian cancer to identify potential diagnostic/prognostic biomarkers in both healthy and tumor tissue,

• LEGGI

• Pubblicazione:
• Annals of Oncology 21:7-1486:1491, 2010 - I.F. 32,97

64 – Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story

• AUTORI: Bari A., Marcheselli L., Sacchi S., Marcheselli R., Pozzi S., Cox MC. et al.

Background: Improved treatment have modified survival outcome in patients with diffuse large B-cell lymphoma (DLBCL) and altered the importance of previously recognized prognostic markers.

• LEGGI

• Pubblicazione:
• Annals of Hematology 90:3-323:330, 2010 - I.F. 3,67

63 – Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL)

• AUTORI: Ferrario A., Merli F., Luminari S., Stelitano C., Mannina D., Russo M., Mazza P., Marcheselli L., Goldaniga M.C., Federico M., Baldini L.

Indolent non-follicular non-Hodgkin lymphomas (INFL) are a heterogenous subset whose treatment has been poorly investigated. In this context we have evaluated the efficacy and

• LEGGI

• Pubblicazione:
• BMC Cancer 10-90, 2010 - I.F. 4,06

61- Favourable ten-year overall survival in a caucasian population with high probability of hereditary breast cancer

• AUTORI: Cortesi L., Masini C., Cirilli C., Medici V., Marchi I., Cavazzini G., Pasini G., Turchetti D., Federico M.

Background: The purpose of our study was to compare differences in the prognosis of breast cancer (BC) patients at high (H) risk or intermediate

• LEGGI

• Pubblicazione:
• Leukemia & Lymphoma 51:4-671:679, 2010 - I.F. 3,28

62 – Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines

• AUTORI: Civallero M., Cosenza M., Grisendi G., Marcheselli L., Todoerti K., Sacchi S.

Immunochemotherapies have improved outcomes in indolent lymphoma. However, response durations progressively shorten following each treatment, and the majority of patients eventually die from the

• LEGGI

• Pubblicazione:
• Leukemia & Lymphoma 51:3-422:429, 2010 - I.F. 3,28

60 – Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi

• AUTORI: Mannina D., Luminari S., Dondi A., Polimeno G., Baldini L., Federico M. et al

We conducted a retrospective analysis on 168 adult patients with newly diagnosed, limited-stage (I and II) diffuse large B-cell lymphoma (DLBCL) treated from 1988

• LEGGI

• Pubblicazione:
• Annals of Oncology 1:4-855:859, 2009 - I.F. 32,97

59 – Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions: results from a population-based study on extranodal marginal zone lymphomas

• AUTORI: Luminari S., Cesaretti M., Marcheselli L., Rashid I., Madrigali S., Federico M. et al.

Background: Few studies have been carried out to date that have addressed the epidemiology of extranodal marginal zone lymphomas (EN-MZLs). Patients and methods: We

• LEGGI

• Pubblicazione:
• Molecular Cancer 8-58, 2209 - I. F. 25,55

58 – Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility

• AUTORI: Luisa Pecorari Oriano Marin, Chiara Silvestri, Olivia Candini, Elena Rossi, Bruno Calabretta et al

Background: Akt/PKB is a serine/threonine kinase that has attracted much attention because of its central role in regulating cell proliferation, survival, motility and angiogenesis.

• LEGGI